MCID: PRS012
MIFTS: 48

Pars Planitis

Categories: Eye diseases, Rare diseases

Aliases & Classifications for Pars Planitis

MalaCards integrated aliases for Pars Planitis:

Name: Pars Planitis 57 12 76 53 44 15 73
Vitritis 53 73
Peripheral Retinal Inflammation 53
Uveitis, Intermediate 73
Intermediate Uveitis 53
Posterior Cyclitis 12

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases


External Ids:

OMIM 57 606177
Disease Ontology 12 DOID:12731
ICD10 33 H30.2
ICD9CM 35 363.21
MeSH 44 D015868
NCIt 50 C34903
SNOMED-CT 68 45688009
MedGen 42 C0030593

Summaries for Pars Planitis

NIH Rare Diseases : 53 Pars planitis is a disease of the eye that is characterized by inflammation of the narrowed area (pars plana) between the colored part of the eye (iris) and the choroid. This may lead to blurred vision; dark, floating spots in the vision; and progressive vision loss. As the condition advances, cataracts, retinal detachment, or macular edema (fluid within the retina) may develop. Pars planitis most often affects young men and is generally not associated with any other disease or symptoms (idiopathic); however, it can be associated with other autoimmune conditions such as multiple sclerosis and sarcoidosis. Treatment typically includes corticosteroid drugs, immunosuppressive medications, and/or surgery.

MalaCards based summary : Pars Planitis, also known as vitritis, is related to uveitis and panuveitis. An important gene associated with Pars Planitis is HLA-A (Major Histocompatibility Complex, Class I, A), and among its related pathways/superpathways are Allograft rejection and Interferon gamma signaling. The drugs Mycophenolic acid and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Intermediate uveitis is a form of uveitis localized to the vitreous and peripheral retina. Primary... more...

Description from OMIM: 606177

Related Diseases for Pars Planitis

Diseases related to Pars Planitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 127)
# Related Disease Score Top Affiliating Genes
1 uveitis 30.8 HLA-B IL1A
2 panuveitis 30.3 HLA-A HLA-B HLA-DRB1
3 cytomegalovirus retinitis 30.2 HLA-A HLA-B
4 acute disseminated encephalomyelitis 29.8 HLA-B HLA-DRB1
5 aphthous stomatitis 29.8 HLA-A HLA-B
6 alopecia areata 29.7 HLA-A IL1A
7 rubella 29.6 HLA-A HLA-B HLA-DRB1
8 graft-versus-host disease 29.4 HLA-A HLA-B HLA-DRB1 IL1A
9 intermediate uveitis 11.7
10 retinal vasculitis 11.3
11 multiple sclerosis 10.4
12 cataract 10.4
13 retinal detachment 10.3
14 macular retinal edema 10.3
15 iridocyclitis 10.2
16 vasculitis 10.1
17 chorioretinitis 10.1
18 echinococcosis 10.1 HLA-B HLA-DRB1
19 dengue shock syndrome 10.1 HLA-A HLA-DRB1
20 palindromic rheumatism 10.1 HLA-A HLA-DRB1
21 microscopic polyangiitis 10.1 HLA-B HLA-DRB1
22 phenytoin or carbamazepine toxicity 10.1 HLA-A HLA-B
23 atrial tachyarrhythmia with short pr interval 10.1 HLA-A HLA-B
24 macular dystrophy, dominant cystoid 10.1
25 3-methylglutaconic aciduria, type iii 10.1
26 retinitis pigmentosa 10.1
27 leber congenital amaurosis 4 10.1
28 crohn's disease 10.1
29 cone dystrophy 10.1
30 posterior uveitis 10.1
31 corneal ectasia 10.1
32 demyelinating disease 10.1
33 retinitis 10.1
34 acute zonal occult outer retinopathy 10.1
35 anterior uveitis 10.1 HLA-A HLA-B
36 chronic pyelonephritis 10.1 HLA-A HLA-B
37 human herpesvirus 8 10.1 HLA-A HLA-B
38 idiopathic neutropenia 10.1 HLA-DRB1 IL1A
39 hematopoietic stem cell transplantation 10.1 HLA-A HLA-B
40 separation anxiety disorder 10.1 HLA-A HLA-B
41 stevens-johnson syndrome/toxic epidermal necrolysis 10.1 HLA-A HLA-B
42 hemorrhagic fever with renal syndrome 10.1 HLA-B HLA-DRB1
43 choroiditis 10.1
44 rheumatic heart disease 10.1 HLA-B HLA-DRB1
45 sclerosing cholangitis 10.0 HLA-B HLA-DRB1
46 autoimmune hepatitis 10.0 HLA-A HLA-DRB1
47 herpes zoster 10.0 HLA-A HLA-B
48 cholangitis 10.0 HLA-B HLA-DRB1
49 spondyloarthropathy 10.0 HLA-A HLA-B
50 bone inflammation disease 10.0 HLA-DRB1 IL1A

Graphical network of the top 20 diseases related to Pars Planitis:



Diseases related to Pars Planitis

Symptoms & Phenotypes for Pars Planitis

Clinical features from OMIM:

606177

GenomeRNAi Phenotypes related to Pars Planitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-103 9.88 HLA-A HLA-B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.88 HLA-A HLA-B
3 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.88 HLA-A HLA-B
4 Increased shRNA abundance (Z-score > 2) GR00366-A-156 9.88 HLA-A HLA-B
5 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.88 HLA-A HLA-B
6 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.88 HLA-A HLA-B
7 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.88 HLA-A HLA-B
8 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.88 HLA-A HLA-B
9 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.88 HLA-A HLA-B

Drugs & Therapeutics for Pars Planitis

Drugs for Pars Planitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
2
Azathioprine Approved Phase 4 446-86-6 2265
3
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2 59-05-2, 1959-05-2 126941
4
Infliximab Approved Phase 4,Phase 1,Phase 2 170277-31-3
5
Chlorambucil Approved Phase 4 305-03-3 2708
6
Cyclophosphamide Approved, Investigational Phase 4 6055-19-2, 50-18-0 2907
7
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
8
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 67-73-2 6215
9
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 1177-87-3
12 Antimetabolites Phase 4,Phase 3,Phase 1,Phase 2
13 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
14 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2
16 Cyclosporins Phase 4
17 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Antitubercular Agents Phase 4,Phase 3
19 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 1,Phase 2
20 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2
21 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Adrenocorticotropic Hormone Phase 4,Phase 2
23 beta-endorphin Phase 4,Phase 2
24 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Melanocyte-Stimulating Hormones Phase 4,Phase 2
28 Antineoplastic Agents, Alkylating Phase 4
29 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Alkylating Agents Phase 4
31 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
33 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1
34
protease inhibitors Phase 4,Phase 2,Phase 3
35 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
38 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
39 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3
40
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
41
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
42
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
43
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
44
Adalimumab Approved Phase 3 331731-18-1 16219006
45
leucovorin Approved Phase 3,Phase 1,Phase 2 58-05-9 6006 143
46
Triamcinolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 124-94-7 31307
47
Fluprednisolone Approved Phase 3 53-34-9
48
Difluprednate Approved Phase 3 23674-86-4 443936
49
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
50
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of H.P. Acthar® Gel in Subjects With Severe Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis NIPPU Recruiting NCT03656692 Phase 4 Acthar
2 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed NCT00132691 Phase 4 fluocinolone acetonide intraocular implant;oral corticosteroid with immunosuppressive agents as needed
3 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
4 Study of the Effectiveness of Ozurdex for the Control of Uveitis Recruiting NCT02049476 Phase 4 Dexamethasone pellet
5 Myfortic for the Treatment of Non-infectious Intermediate Uveitis Completed NCT01092533 Phase 3 Myfortic;Decortin
6 Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis Completed NCT00344253 Phase 3 Interferon beta;Methotrexate
7 Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis Completed NCT01124838 Phase 3 Adalimumab;Prednisone;Placebo
8 38 Week Extension Study to CAIN457C2303 Terminated NCT01093846 Phase 3 AIN457;AIN457;Placebo AIN457
9 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Completed NCT00333814 Phase 2, Phase 3 Dexamethasone;dexamethasone;Sham injection
10 Efficacy and Safety of Adalimumab in Patients With Active Uveitis Completed NCT01138657 Phase 3 Prednisone;Placebo
11 Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis Terminated NCT01095250 Phase 3 AIN457;AIN457;AIN457;Placebo
12 Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis Terminated NCT01032915 Phase 3 Placebo
13 A Controlled, Multi-center Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye Completed NCT02748512 Phase 3 FAI insert
14 Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Posterior Uveitis Active, not recruiting NCT02746991 Phase 3 Sham Injection;FAI Insert
15 Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert Active, not recruiting NCT01694186 Phase 3 FAI insert;Sham injection
16 Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis Completed NCT03097315 Phase 3
17 Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis Completed NCT02595398 Phase 3 4mg CLS-TA Suprachoriodal Injection;Sham Procedure
18 Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis Withdrawn NCT01327664 Phase 3
19 Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X) Terminated NCT02375685 Phase 3
20 Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis Terminated NCT01103024 Phase 3
21 Phase III Study in Refractory Behcet's Disease Completed NCT00995709 Phase 3 AIN457;AIN457;Placebo
22 Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment Terminated NCT01747538 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
23 Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis Terminated NCT01684345 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
24 Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery Completed NCT01124045 Phase 3 Difluprednate ophthalmic emulsion, 0.05%;Prednisolone acetate ophthalmic suspension, 1.0%
25 A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis Completed NCT01148225 Phase 3 adalimumab
26 An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data Terminated NCT02258854 Phase 3 Dose 2 gevokizumab
27 A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
28 A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
29 Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis Terminated NCT01090310 Phase 3 AIN457;Placebo
30 A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis Completed NCT00988221 Phase 3 Tocilizumab;Placebo
31 Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis Completed NCT01201798 Phase 3 Difluprednate 0.05% ophthalmic emulsion;Prednisolone acetate 1.0% ophthalmic suspension
32 Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis Completed NCT00615693 Phase 2 AEB071
33 Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study Active, not recruiting NCT01717170 Phase 1, Phase 2 Tocilizumab
34 Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis , Completed NCT01526889 Phase 2 LFG316;Conventional Therapy
35 Safety &Efficacy of CF101 to Subjects With Uveitis Withdrawn NCT01905124 Phase 2 CF101;Placebo
36 Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis Completed NCT01789320 Phase 1, Phase 2 triamcinolone acetonide (Triesence®)
37 Intravitreal Sirolimus as Therapeutic Approach to Uveitis Recruiting NCT01280669 Phase 2 Intravitreal injection 440mcg;Intravitreal injection of sirolimus 880mcg
38 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
39 Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study) Recruiting NCT02911116 Phase 2 Ustekinumab
40 Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit Recruiting NCT02863809 Phase 1, Phase 2 Riboflavin;Dextran
41 Topical Interferon Gamma for Macular Edema Secondary to Uveitis Completed NCT01376362 Phase 1, Phase 2 Interferon Gamma-1b
42 Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis Completed NCT02255032 Phase 2 4 mg CLS-TA;0.8 mg CLS-TA
43 ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study) Recruiting NCT02931175 Phase 2 ACTH gel
44 Safety and Preliminary Efficacy Study of V404 PDS in Uveitis Terminated NCT02125266 Phase 1, Phase 2 V404
45 Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study Completed NCT02620618 Phase 1, Phase 2 Intravitreal Infliximab
46 A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis Withdrawn NCT00499551 Phase 1, Phase 2
47 Leflunomide to Treat Uveitis Completed NCT00001863 Phase 2 Leflunomide
48 Safety and Efficacy of AIN457 in Noninfectious Uveitis Completed NCT00685399 Phase 2 AIN457;AIN 457;AIN457
49 Sirolimus as Therapeutic Approach to Uveitis Completed NCT00908466 Phase 1 Sirolimus (rapamycin);Sirolimus (rapamycin)
50 The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma Completed NCT00943982 Phase 1 Interferon Gamma 1-b

Search NIH Clinical Center for Pars Planitis

Cochrane evidence based reviews: pars planitis

Genetic Tests for Pars Planitis

Anatomical Context for Pars Planitis

MalaCards organs/tissues related to Pars Planitis:

41
Eye, Retina, Endothelial, T Cells, B Cells, Bone, Heart

Publications for Pars Planitis

Articles related to Pars Planitis:

(show top 50) (show all 143)
# Title Authors Year
1
Cataract, Vitritis, and Diffuse Hypofluorescent Retinal Dots on Fluorescein Angiography. ( 29392284 )
2018
2
Bilateral cystoid macular edema misdiagnosed as pars planitis in a patient on sertraline therapy. ( 29984334 )
2018
3
Progression of retinal pigmentation mimicking unilateral retinitis pigmentosa after bilateral pars planitis: a case report. ( 30200907 )
2018
4
FULL DIAGNOSTIC VITRECTOMY WITH POSTERIOR VITREOUS DETACHMENT INDUCTION FOR THE DIAGNOSIS OF VITRITIS DUE TO UNCERTAIN ETIOLOGY. ( 30005004 )
2018
5
Pars Planitis ( 28613790 )
2017
6
Challenges with cataract surgery in pars planitis patients. ( 28593425 )
2017
7
Analysis of clinical features and visual outcomes of pars planitis. ( 28389773 )
2017
8
Outcomes of cataract surgery with/without vitrectomy in patients with pars planitis and immunosuppressive therapy. ( 28396945 )
2017
9
Peripheral Cryoablation for Treatment of Active Pars Planitis: Long-Term Outcomes of a Retrospective Study. ( 26576712 )
2016
10
Retinoschisis in Pars Planitis. ( 26902143 )
2016
11
Scleral Buckling for Rhegmatogenous Retinal Detachment Associated with Pars Planitis. ( 27688907 )
2016
12
Evaluation of Objective Vitritis Grading Method Using Optical Coherence Tomography: Influence of Phakic Status and Previous Vitrectomy. ( 26476212 )
2016
13
NONINFECTIOUS VITRITIS AFTER INTRAVITREAL INJECTION OF ANTI-VEGF AGENTS: Variations in Rates and Presentation by Medication. ( 27115856 )
2016
14
Management of Retinal Whitening With Vitritis. ( 27196726 )
2016
15
Primary Intraocular Diffuse Large B-cell Lymphoma: Diagnostic Difficulties in Deep Retinal Infiltrations with Vitritis. ( 27408377 )
2016
16
A 12-Year-Old Boy with Pars Planitis. ( 26587811 )
2015
17
Immunopathogenic Background of Pars Planitis. ( 26438050 )
2015
18
Rhegmatogenous retinal detachment due to a macular hole in a patient with pars planitis: a case report. ( 25565856 )
2015
19
Pars Planitis: Epidemiology, Clinical Characteristics, Management and Visual Prognosis. ( 27051493 )
2015
20
Vitritis in pediatric genetic retinal disorders. ( 25217415 )
2015
21
Bilateral effect of unilateral dexamethasone intravitreal implant in a case of noninfectious uveitic macular edema and vitritis. ( 25462131 )
2015
22
Idiopathic vitritis in the setting of Boston keratoprosthesis. ( 25526075 )
2015
23
Topical dexamethasone-cyclodextrin nanoparticle eye drops for non-infectious Uveitic macular oedema and vitritis - a pilot study. ( 25988730 )
2015
24
Treatment with immunosuppressive therapy in patients with pars planitis: experience of a reference centre in Mexico. ( 24985727 )
2014
25
Peripapillary choroidal neovascularization in pars planitis. ( 23514324 )
2013
26
Association of epiretinal membranes with macular edema in pars planitis. ( 24332688 )
2013
27
Four years old, one eye, pars planitis and cataract: surgical challenges give challenging surprises. ( 23626571 )
2013
28
Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome. ( 25389947 )
2012
29
Effects of twice-daily topical difluprednate 0.05% emulsion in a child with pars planitis. ( 21034305 )
2011
30
Childhood pars planitis; clinical features and outcomes. ( 22454747 )
2011
31
Corneal ectasia secondary to peripheral endotheliopathy in a patient with classic pars planitis. ( 21484170 )
2011
32
Keratoprosthesis sterile vitritis. ( 21199717 )
2011
33
[Clinical and epidemiological features and HLA association in patients with pars planitis]. ( 20537664 )
2010
34
Paraneoplastic granulomatous vitritis and retinitis as a presentation of recurrent classical Hodgkin's lymphoma. ( 20076991 )
2010
35
Peptidic sequence "HSEAETGPP" is recognized by the sera of pars planitis patients. ( 19480736 )
2009
36
Fuchs' Uveitis: Failure to Associate Vitritis and Disc Hyperfluorescence with the Disease is the Major Factor for Misdiagnosis and Diagnostic Delay. ( 20404990 )
2009
37
Vitritis as the initial manifestation of recurrent mycosis fungoides. ( 25389573 )
2009
38
Acute zonal occult outer retinopathy (AZOOR) and pars planitis: a new association? ( 18369082 )
2008
39
Pars planitis: a 20-year study of incidence, clinical features, and outcomes. ( 18724984 )
2008
40
Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin). ( 17934693 )
2008
41
Pars planitis: a 20-year study of incidence, clinical features, and outcomes. ( 18036872 )
2007
42
Pars planitis is associated with an increased frequency of effector-memory CD57+ T cells. ( 17475702 )
2007
43
Pars planitis in children: epidemiologic, clinical, and therapeutic characteristics. ( 17913171 )
2007
44
The enigma of pars planitis, revisited. ( 16564810 )
2006
45
Correlation between clinical suspicion and polymerase chain reaction verification of infectious vitritis. ( 16490520 )
2006
46
Immune recovery vitritis in an HIV patient with isolated toxoplasmic retinochoroiditis. ( 17086067 )
2006
47
Clinical symptoms and complications of pars planitis in childhood. ( 15849986 )
2005
48
The appearance of pars planitis in multiple sclerosis. ( 16117323 )
2005
49
Valsalva retinopathy: diagnostic challenges in a patient with pars-planitis. ( 15799745 )
2005
50
Sudden reversible vitritis after keratoprosthesis: an immune phenomenon? ( 16227832 )
2005

Variations for Pars Planitis

Expression for Pars Planitis

Search GEO for disease gene expression data for Pars Planitis.

Pathways for Pars Planitis

Pathways related to Pars Planitis according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.41 HLA-A HLA-B HLA-DRB1 IL1A
2
Show member pathways
12.16 HLA-A HLA-B HLA-DRB1
3
Show member pathways
12.13 CD27 HLA-A HLA-B HLA-DRB1 IL1A
4 12.06 HLA-A HLA-B HLA-DRB1
5
Show member pathways
11.95 HLA-A HLA-B HLA-DRB1 IL1A
6
Show member pathways
11.9 HLA-A HLA-B IL1A
7 11.88 HLA-A HLA-B HLA-DRB1
8 11.7 HLA-A HLA-B IL1A
9
Show member pathways
11.61 HLA-A HLA-DRB1
10 11.61 HLA-A HLA-B HLA-DRB1
11
Show member pathways
11.58 HLA-A HLA-DRB1
12 11.52 HLA-DRB1 IL1A
13 11.49 HLA-A HLA-B HLA-DRB1
14 11.48 HLA-DRB1 IL1A
15 10.92 HLA-DRB1 IL1A
16 10.83 HLA-A HLA-B

GO Terms for Pars Planitis

Cellular components related to Pars Planitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi membrane GO:0000139 9.61 HLA-A HLA-B HLA-DRB1
2 external side of plasma membrane GO:0009897 9.5 CCR7 CD27 HLA-DRB1
3 recycling endosome membrane GO:0055038 9.4 HLA-A HLA-B
4 phagocytic vesicle membrane GO:0030670 9.37 HLA-A HLA-B
5 cell surface GO:0009986 9.35 CCR7 CD27 HLA-A HLA-B HLA-DRB1
6 ER to Golgi transport vesicle membrane GO:0012507 9.33 HLA-A HLA-B HLA-DRB1
7 MHC class I protein complex GO:0042612 9.26 HLA-A HLA-B
8 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.8 HLA-A HLA-B HLA-DRB1

Biological processes related to Pars Planitis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.69 HLA-A HLA-B HLA-DRB1
2 positive regulation of JNK cascade GO:0046330 9.49 CCR7 CD27
3 type I interferon signaling pathway GO:0060337 9.48 HLA-A HLA-B
4 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.46 HLA-A HLA-B
5 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent GO:0002479 9.43 HLA-A HLA-B
6 positive regulation of T cell mediated cytotoxicity GO:0001916 9.4 HLA-A HLA-B
7 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.37 HLA-A HLA-B
8 interferon-gamma-mediated signaling pathway GO:0060333 9.33 HLA-A HLA-B HLA-DRB1
9 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.32 HLA-A HLA-B
10 protection from natural killer cell mediated cytotoxicity GO:0042270 9.26 HLA-A HLA-B
11 antigen processing and presentation GO:0019882 9.13 HLA-A HLA-B HLA-DRB1
12 immune response GO:0006955 9.02 CCR7 HLA-A HLA-B HLA-DRB1 IL1A

Molecular functions related to Pars Planitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.8 HLA-A HLA-B HLA-DRB1

Sources for Pars Planitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....